首页> 美国卫生研究院文献>Journal of Diabetes Science and Technology >Glucagon: Physiology and Pharmacotherapy: Efficacy Determinants of Subcutaneous Microdose Glucagon during Closed-Loop Control
【2h】

Glucagon: Physiology and Pharmacotherapy: Efficacy Determinants of Subcutaneous Microdose Glucagon during Closed-Loop Control

机译:胰高血糖素:生理学和药物治疗:闭环控制过程中皮下微剂量胰高血糖素的功效决定因素

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundDuring a previous clinical trial of a closed-loop blood glucose (BG) control system that administered insulin and microdose glucagon subcutaneously, glucagon was not uniformly effective in preventing hypoglycemia (BG <70 mg/dl). After a global adjustment of control algorithm parameters used to model insulin absorption and clearance to more closely match insulin pharmacokinetic (PK) parameters observed in the study cohort, administration of glucagon by the control system was more effective in preventing hypoglycemia. We evaluated the role of plasma insulin and plasma glucagon levels in determining whether glucagon was effective in preventing hypoglycemia.
机译:背景在先前的皮下注射胰岛素和小剂量胰高血糖素的闭环血糖(BG)对照系统的临床试验期间,胰高血糖素在预防低血糖方面(BG <70 mg / dl)并非统一有效。在对用于模拟胰岛素吸收和清除的模型的控制算法参数进行整体调整以更匹配研究队列中观察到的胰岛素药代动力学(PK)参数之后,通过控制系统施用胰高血糖素可更有效地预防低血糖症。我们评估了血浆胰岛素和血浆胰高血糖素水平在确定胰高血糖素是否有效预防低血糖中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号